GlobeNewswire·Jan 8, 2026, 8:00 AM ET

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Pooled patients treated with TTI-101 showed a 9.4% decrease in fibrosis score at week 12 compared to a 2.4% decrease for the placebo group.
The final analysis dataset included 40 patients: 16 receiving TTI-101 & 24 receiving placebo, after removing four patients for dosing, pharmacokinetic, or outlier reasons.
TTI-101 treatment resulted in greater declines in IL-6 inflammatory markers than placebo, particularly in patients with higher baseline levels.
63% of TTI-101 patients demonstrated an increase in FVC at 12 weeks versus 46% in the placebo group.
Mean FVC change for TTI-101 patients was -15mL, showing less decline than the REVERT placebo group (-22mL) & historical placebo controls.
Topline data from the Phase 1 study of the next-generation STAT3 inhibitor TTI-109 is on track for release in H1 2026.
The REVERT IPF Phase 2 trial was a randomized, double-blind, placebo-controlled study that did not meet its primary goals when preliminary safety & efficacy data were reviewed in October 2025.
TTI-109 is designed to improve STAT3 targeting efficiency & tolerability compared to TTI-101.